3SOF

Profile Get Profile for:   

Provectus Pharmaceuticals Inc.
7327 Oak Ridge Highway
Suite A
Knoxville, TN 37931
Phone: 865-769-4011
Web Site: http://www.provectuscorp.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 5


BUSINESS SUMMARY   
Provectus Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development, licensing, and marketing of over-the-counter (OTC) products, prescription drugs, and medical device systems. The company's OTC products include disposable gloves and Pure-ific line of products, including two quick-drying sprays, Pure-ific and Pure-ific Kids, which address problems, such as hand irritation associated with use of disposable gloves, eczema, and mild to moderate acne. Its prescription drugs provide invasive treatment of chronic severe skin afflictions, such as psoriasis, eczema, and acne; and various life-threatening cancers, such as those of the liver, breast, and prostate. The company is also developing medical devices for cosmetic treatments, such as reduction of wrinkles and elimination of spider veins and other cosmetic blemishes, as well as for therapeutic uses, including photoactivation of its prescription drugs and nonsurgical destruction of certain skin cancers. Provectus Pharmaceuticals was incorporated in 1978 and is based in Knoxville, Tennessee.

Interesting company here,recent insider buying.
The news on,  funding, patents & trials is all a big plus
The Stock:
Looks pretty good here. Low volume, although the chart  looks like the chart of a more mature company.
It does look  good,could be a very good mid-long term play, and may even be a good win in the short term.
Looking to buy any kind of a pull back here.

Float (mil) 23.40 Shares Outstanding (mil) 35.47

Volume: 426,695
Avg Vol (3m): 174,937

Technicals
Record Price High

Last Price Quote is:
22.57%above 13-day EMA

Back above the 50/ 200-day MA
could be nearing a Golden Cross....

Technicals
Percentage Gainer

Last Price Quote is:
2.18%above 13-day EMA

Press Release Source: Provectus Pharmaceuticals, Inc.


Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Wednesday September 5, 8:30 am ET 
Study Builds on Phase 1 Safety and Efficacy Results for Provecta(TM)


KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT - News) announced today that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.


In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, "Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease." Dees continued, "Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future."

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective and less invasive than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs Provecta(TM) (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl(TM), a topical treatment for severe psoriasis and eczema. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.


Contact:
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 865-769-4011
or
The Investor Relations Group
Investor Relations: Joseph Kessler
Media: Janet Vasquez
212-825-3210

--------------------------------------------------------------------------------
Source: Provectus Pharmaceuticals, Inc.

Nice...
Well, its been a while. New investment firm, news about phase two! 
The low float can drive this up quickly...low float of 11.5m
The news on...funding, patents & trials is all a big plus !


52wk Range: 1.00 - 2.14
Volume: 1,491,314
Avg Vol (3m): 94,584.8

Technicals
Record Volume
Record Price High
Percentage Gainer

Last Price Quote is:
23.09%above 13-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $96.10 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

Below are the 6 month and 3 Year charts.......

Provectus Pharmaceuticals (PVCT.OB)
in very heavy trading after getting clearance for midphase testing on Provecta, which is proposed to treat stage III and IV metastatic melanoma -- an advanced form of skin cancer. Shares of the Knoxville, Tenn., company were up 39 cents to $2.80.


52wk Range: 1.00 - 3.04
Volume: 1,286,287
Avg Vol (3m): 198,912

Technicals
Last Price Quote is:
22.34%above 13-day MA

CEO Comments on Ph II Trial
of Provecta(TM)
Shares of Provectus Pharmaceuticals Inc (PVCT) hit a 52-week high
on Thursday and continued to advance on Friday. The Company received
approval to launch a Phase 2 clinical trial of Provecta(TM) for
the treatment of Stage III and IV metastatic melanoma, the most aggressive
and deadly form of skin cancer. The multi-center study is designed to evaluate
efficacy of Provecta in a total of 80 subjects. The lead site for the study is the Sydney
Melanoma Unit in Australia. Over the next several months the study will expand
to include sites in a number of major population centers in Australia as well as several sites in the U.S.
Preliminary analysis of data from Phase 1 showed that Provecta, which has received orphan drug designation
in the U.S., was well tolerated with generally mild side effects.
Craig Dees, Ph.D., Chief Executive Officer of Provectus, told Knobias on Friday, "One key advantage
of Provecta is that it is specific to diseased cells, leaving healthy cells unharmed. Additionally, treatment
with Provecta has been show to stimulate an anti-tumor immune response once the injected tumors are
ablated. Provecta can also be combined with radiation, increasing the effects of radiation on tumor tissue
and potentially enabling less radiation to be used, thereby subjecting patients to fewer side effects."
"The use of Provecta, or Rose Bengal as active ingredient, was discovered by the founders of Provectus,
who are ex-Oak Ridge National Laboratory scientists. Through the application of their unique skill sets,
these scientists innovated the use of Rose Bengal as a therapeutic rather than a diagnostic. Nobody else
is trying to do we are doing, which is taking a compound such as Rose Bengal, and using it as a therapeutic.
Our competitors are typically taking a genetic engineering approach, rather than the classic small
molecule approach which we are utilizing."
The Company is also conducting clinical trials for Xantryl(TM), a topical treatment for severe psoriasis
and eczema. Xantryl is active only in abnormal or diseased tissues, making it safer to use than existing
products. The active ingredient in Xantryl is also Rose Bengal. The Company will be able to cost-efficiently
develop both products for different markets because they share many manufacturing, characterization and
regulatory elements.
Psoriasis is a common chronic disorder of the skin characterized by dry scaling patches for which current
treatments are few and those that are available have potentially serious side effects. Psoriasis has been
reported to affect approximately 2% of the world's population, and there is no known cure for the disease
at this time. Severe cases generally are treated with intensive drug therapies or a light-based therapy that
combines the drug Psoralen with exposure to ultraviolet A light. This treatment has been shown to increase
the risk for cancers of the skin. Warner Chilcott's (WCRX) Dovonex(R) is a form of synthetic vitamin D3
approved by the FDA for treating psoriasis. It slows down the rate of skin cell growth, flattens psoriasis
lesions and removes scale, but it is not effective at decreasing inflammation.
Eczema is a dermatitis (inflammation) of the upper layers of the skin. It occurs in atopic people and people
who are extra sensitive to skin irritation. Dry, flaky skin appears over red, inflamed areas, causing intense
itching and burning. Psoralen with ultraviolet light, antibiotics, corticosteroids and antifungal creams are
common treatments. Novartis'(NVS) Elidel(R) controls the condition by suppressing the immune system.
Elidel has been found to increase the risk cancer and non-Hodgkin's lymphoma.
As of June 30, 2007, the Company had $6.8 million in cash and United States Treasury Notes and an accumulated
deficit of $39.9 million.
Dr. Dees noted, "Within the next year we plan to have three active indications for oncology, and two for
dermatology, with treatments covering metestatic melanoma, liver cancer, breast cancer, psoriasis and
eczema. We now have U.S. sites that will be part of our Phase 2 clinical trials of Provecta, as well as U.S.
sites for Phase 2 clinical trials for Xantryl."
He concluded, "We believe that the earliest time we would enter the oncology market is at the end of
2009. This belief is predicated on the significant need for treatments for metastatic melanoma, which we
hope will lead to an accelerated approval. We have all of the necessary funds to continue to advance
development of Provecta through the end of 2008. The Company has entered discussions for strategic
agreements. On a licensing level, we could be profitable as early as mid-to-late 2008 with Xantryl. On a
commercialization level, we are projecting profitability by late 2009."

Nice indeed...

52wk Range: 1.00 - 3.04
Volume: 1,153,481
Avg Vol (3m): 205,840

Technicals
Record Price High
Gap Up
Percentage Gainer

Last Price Quote is:
31.20%above 13-day MA
inf%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $128.13 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

Press Release Source: Provectus Pharmaceuticals, Inc.


Provectus Receives Patent Protection Notice From European Patent Office
Wednesday September 12, 8:00 am ET


KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News) announced today it has received allowance of its patent application protecting its flagship product, Provecta(TM), from the European Patent Office (EPO). This allowance follows several successful U.S. filings for patent protection and is the second international case covering the intellectual property of Provecta. In December 2006, the Company announced similar allowance by the Intellectual Property Office of Taiwan (TIPO).


The pending patent covers certain formulations and medical uses of Provecta, a novel formulation of rose bengal, also called PV-10, as a medicament for treatment of cancer and other serious diseases. Provecta is currently undergoing phase 2 clinical testing for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer.

"We are pursuing patent protection for Provecta and other intellectual properties, such as Xantryl(TM), our topical formulation of rose bengal for psoriasis and other skin diseases, in key markets worldwide," notes Provectus CEO Craig Dees, Ph.D. "Success in obtaining protection with several of our U.S. filings and now with this important case in Europe validates the value of our science and our global intellectual property strategy to build value for our shareholders."

Dees continued, "As we increase the pace of our clinical trials of Provecta for a number of different indications, we believe that aggressively protecting these intellectual assets will be vital to our eventual marketing success," said Dees.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs Provecta(TM) (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl(TM), a topical treatment for severe psoriasis and eczema. The company expects to commence Phase 2 clinical testing of Provecta for melanoma in the near future. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Initial Phase 1 clinical trial objectives for Provecta for breast cancer were completed in April 2006, but the trial was extended to more properly determine optimal dosing. The extended Phase 1 trial is also nearing completion and the company anticipates reporting those results in the near future. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnology. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Contact:
The Investor Relations Group
Investor Relations:
Joseph Kessler
or
Media:
Janet Vasquez, 212-825-3210
or
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 865-769-4011

--------------------------------------------------------------------------------
Source: Provectus Pharmaceuticals, Inc.

Press Release Source: Provectus Pharmaceuticals, Inc.


Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study
Tuesday September 18, 7:00 am ET 
Provecta(TM) demonstrates minimal side effects, significant efficacy and bystander effect on melanoma tumors in 20 stage III patients


KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News) announced today preliminary results of its Phase 1 clinical trial of Provecta(TM) for the treatment of metastatic melanoma, the most aggressive form of skin cancer. Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients. The study evaluated safety and efficacy of Provecta in a total of 20 subjects at two sites in Australia

In the study, Provecta was injected once into one to twenty tumors in each subject. In addition to these treated tumors, an additional one to three tumors were left untreated in each subject to allow assessment of a potential "bystander effect" resulting from immune system response to tumor treatment. A total of 114 tumors were injected and 39 bystander tumors were observed in the study. Subjects were followed for 4 to 27 weeks. Study treatments were well tolerated and elicited minimal side effects, the most common being mild to moderate pain at the injection site.

Results for all evaluable tumors were tabulated using the RECIST (Response Evaluation Criteria in Solid Tumors) approach, which objectively grades response for each subject based on change in the sum of the longest diameter for each of the subject's tumors vs. baseline. Subject outcome was scored in terms of complete response (CR - complete tumor disappearance or negative histopathology), partial response (PR - 30% or more tumor shrinkage), stable disease (SD - 29% shrinkage to 20% growth), and progressive disease (PD - greater than 20% growth).

At final evaluation after injection with a single dose of Provecta, the following results were obtained: 20% of subjects achieved CR of their injected tumors, 20% achieved PR, 35% achieved SD and 25% achieved PD, corresponding to an objective response (CR+PR) in 40% of subjects and local disease control (CR+PR+SD) in 75% of subjects. Among those subjects achieving an objective response of their treated tumors, 25% achieved an objective response of their untreated bystander tumors, and 100% exhibited disease control in their bystander tumors. In contrast, for those subjects failing to achieve an objective response of their treated tumors, only 8% achieved an objective response of their bystander tumors, and 92% exhibited progressive disease in their bystander tumors. These differences in response of bystander lesions as a function of response of target lesions were statistically significant and support the occurrence of a bystander effect in subjects whose target lesions have been responsive to PV-10 chemoablation.

Craig Dees, Ph.D., Chief Executive Officer of Provectus stated, "While full analysis of our phase 1 data is yet to be completed and will be reported by other means, the significance of these top line numbers is compelling and serves to illustrate the unique properties of Provecta. Additionally, they reinforce the confidence level we've had since we first witnessed the effects of this drug for the treatment of melanoma. These results have motivated us to put forth an aggressive clinical plan designed to drive toward approval of Provecta for this devastating disease." Dees continued, "The response from the body's own immune system to those tumors that were left untreated makes our novel approach to treating the disease that much more attractive."

About Provectus Pharmaceuticals

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective and less invasive than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs Provecta(TM) (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl(TM), a topical treatment for severe psoriasis and eczema. See www.clinicaltrials.gov for a description of the Provectus Metastatic Melanoma Phase 2 clinical trial. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnology. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.


Contact:
The Investor Relations Group
Investor Relations:
Joseph Kessler, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210
or
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 865-769-4011

--------------------------------------------------------------------------------
Source: Provectus Pharmaceuticals, Inc.